11
B i o T O P i c s 4 2 _
B i o T O P R e p o r t 2 0 1 1
PAREXEL International GmbH
PAREXEL International is a leading glob-
al biopharmaceutical services organiza-
tion, providing a broad range of knowl-
edge-based contract research, medical
communications and consulting services
to the worldwide pharmaceutical, bio-
technology and medical device indus-
tries. Committed to providing solutions
that expedite time-to-market and
peak-market penetration, PAREXEL has
developed significant expertise across
the development and commercialization
continuum, from drug development and
regulatory consulting to clinical phar-
macology, clinical trials management,
medical education and reimbursement.
Perceptive Informatics, Inc., a subsidiary
of PAREXEL, provides advanced technol-
ogy solutions, including medical imag-
ing, to facilitate the clinical develop-
ment process. Headquartered near Bos-
ton, Massachusetts, PAREXEL operates in
71 locations throughout 52 countries
around the world, and has approxi-
mately 10,380 employees.
PAREXEL has a long-standing presence in
Berlin, where over 1,500 employees are
located. Clients can benefit from state-
of-the-art technologies and equipment
provided through PAREXEL’s medical
imaging lab and Early Phase Units,
which provide a safe, high-quality
environment for early phase develop-
ment activities in a hospital setting. The
PAREXEL Academy located in Berlin qual-
ifies clinical research associates and
clinical data managers, and offers a
course for a Bachelor of Science degree
in Clinical Research, validated by a Brit-
ish university.
Address
PAREXEL International GmbH
Klinikum Westend · Haus 18
Spandauer Damm 130
14050 Berlin · Germany
Contact
Dr. Ulf Schneider
Senior Vice President and
Chief Administrative Officer
PAREXEL International
Phone +49 30 30685 115
Fax
+49 30 30685 7115
ulf.schneider@parexel.com
www.parexel.com
ORGANOBALANCE GmbH
In Harmony with Nature
ORGANOBALANCE is specializing in micro-
bial strain develop ment and screening.
The company taps into the potential of
beneficial microorganisms, known as
specific probiotic cultures, to compen-
sate imbalances in the microflora and
restore the microbial equilibrium. In
close cooperation with leading indus try
partners ORGANOBALANCE develops new
biological products in the areas of nutri-
tion, cosmetics and preventive health
care. In its development activities, the
company draws on its own collection of
microorganism strains suitable for food
applications and its OASSYS
®
screening
systems.
Using innovative screening technologies
and individually configured test designs,
those strains of microorganisms are fil-
tered that match application-specific
criteria. For suitable strains, fermenta-
tion and downstream processes are
devel oped in a pilot scale production
facility.
In a long-term partnership with leading
international companies ORGANOBAL-
ANCE developed marketable strains of
probiotic cultures that combat tooth
decay, body odour and skin irritation on
a natural basis. Own product develop-
ments are pursued. Examples of targets
include gastrointestinal health and
microorganisms with preservative effect.
ORGANOBALANCE has a comprehensive
knowledge and experience in the field
of industrial biotechnology and devel-
ops strains by means of metabolic engi-
neering.
Address
ORGANOBALANCE GmbH
Gustav-Meyer-Allee 25
13355 Berlin · Germany
Contact
Dr. Christine Lang · CEO
Phone +49 30 46307200
Fax
+49 30 46307210
info@organobalance.com
www.organobalance.com
12
B i o T O P i c s 4 2 _
B i o T O P R e p o r t 2 0 1 1
Prof. Dr. Roland Lauster
Director of the Department of Medical Biotechnology
and Managing Director of the Biotechnology Institute
at Technische Universität Berlin
The term regenerative medicine denotes the development and
application of innovative medical therapies using biomaterials,
cells and hybrid organs. This rapidly expanding interdisciplinary
research field combines the methods of clinical medicine (e. g.
orthopaedics, surgery, intensive and transplantation medicine)
with molecular and cell biology (genomics, proteomics, stem cell
research), chemistry and biochemistry, pharmacology as well as
the engineering and materials sciences (biomaterials, bioengi-
neering), bioinformatics, medical engineering and nanotech-
nology. Berlin Brandenburg has taken up the challenge to bring
together these diverse research approaches in order to accelerate
the development of new therapies.
Translational Research
The Berlin Brandenburg Center for Regenerative Therapies (BCRT)
is a center for translational research of the German Federal Min-
istry of Education and Research, and a joint initiative of Europe’s
largest university hospital, the Charité, and Germany’s largest
research organization, the Helmholtz association. The program
focuses on endogenous regenerative therapies and is putting
particular emphasis on research and clinical programs related to
musculoskeletal, cardiovascular and immunological applications,
since these aspects of regenerative medicine are most advanced
at the Charité and closest to clinical translation. These medical
research fields are linked to overlapping platforms on basic, bio-
materials, and translational research.
The BCRT is located in a newly reconstructed building at the Chari-
té Campus Virchow Clinic. It is host to 26 newly implemented
research groups. 19 groups are funded by the German Ministry for
Education and Research, four groups are funded by the Helmholtz
Association and three by the Deutsche Forschungsgemeinschaft
(DFG).
For the interdisciplinary training of young scientists in the field
of regenerative medicine in 2008 the Berlin-Brandenburg School
for Regenerative Therapies (BSRT) was established as a graduate
school of the German Excellence Initiative. It offers outstanding
training and research opportunities for doctoral researchers in the
biological and engineering disciplines and for clinical scientists.
In 2010 the BCRT has been positively evaluated by the German
Ministry for Education and Research and therefore secured fund-
ing for another four years.
Exploring the Regenerative Potential of the
Human Body
Regenerative medicine is one of the research areas that have developed particularly fast
in recent years. The capital region has been one of the pioneers in the field in the 1990s
and has since built up important institutions, notably the Berlin Brandenburg Center for
Regenerative Therapies (BCRT) and the Regenerative Medicine Initiative Berlin-Branden-
burg (RMIB).
The Report “Regenerative Medizin in Berlin
Brandenburg” (in German language) is available
for download at www.rmib.de
1
Technologiereport Regenerative Medizin in Berlin-Brandenburg
Inhalt
Technologiereport
Regenerative Medizin
in Berlin-Brandenburg
Chips Instead of Animals
»
In the coming years, we expect the legal environment to
develop and generate strong
demand for a reduction in
animal experiments. Our Multi-Organ Bioreactor in chip for-
mat permits reducing the number of substances requiring
animal testing significantly because all substances that prove
toxic on the chip no longer need to be tested in animals.